Column List | SMC Laboratories Inc.

2025.02.03

Drug efficacy studies in NASH mouse model

Today, we would like to introduce a paper published by our client using our non-alcoholic steatohepatitis (NASH) model. (Yang et al., Int J Biol Sci., 2021). This paper focuses on the prevention of the progression of NASH-derived liver cancer, which has attracted a lot of attention in recent years. After analyzing their target based…

2025.02.03

Preclinical studies for IBD research: DSS model

We would like to introduce the dextran sulfate sodium (DSS) -induced colitis model, which is a clinically representative mouse model that can be used to conduct drug efficacy studies targeting Inflammatory Bowel Disease. This model is widely used to elucidate the mechanism of IBD pathogenesis and evaluate drug candidates because of its rapidity, simplicity…

2025.02.03

Advantages of using multiple MASH models: STAM x GAN diet

Advantages of using multiple MASH models; STAMTM x GAN diet – Comprehensively covers criteria for MASH patients in clinical trials – Using GAN diet with STAMTM comprehensively covers obesity, steatosis score, and fibrosis score Comparison table; STAMTM x GAN diet Several ideal MASH models have been described in the literature, but currently…

2025.02.03

Expanding Our IPF Services: Introducing Male Mouse Models for Drug Efficacy Evaluation Studies

We would like to inform you that we have extended our drug efficacy evaluation study services for male bleomycin (BLM)-induced lung fibrosis mouse model. Idiopathic pulmonary fibrosis (IPF) is a lung disease that causes fibrosis in the lungs, and is more common in men than in women. Until now, we have primarily used female…

2025.02.03

The STAM Model in NASH fundamental research

We would like to share some examples of how our NASH-HCC model (STAMTM model) can be used for fundamental research. NASH is a disease area in which great demand remains in fundamental research such as elucidation of pathogenic mechanisms and development of new diagnostic methods. Fundamental research is often conducted using animal disease…

2025.02.03

RNA sequencing data from STAM mice

We would like to introduce the acquisition of RNA sequencing data from STAMTM mice which we hope to utilize to offer our clients high value proposals. The STAMTM mouse is used as a NASH-HCC model that shows similar pathology to human NASH (fatty liver → NASH → liver fibrosis → HCC), and has been…

2025.02.03

Nerandomilast: Breakthrough Success in Phase 3

We would like to introduce the data we obtained from a recently conducted bleomycin-induced lung fibrosis study using Nerandomilast. Nerandomilast is a compound expected to be approved soon as a treatment for IPF, following the previously approved Pirfenidone and Nintedanib. The mentioned therapeutic study using Nerandomilast in a bleomycin-induced lung fibrosis model that…

2025.02.02

Comparative Study of GLP-1 Agonists

Direct comparison study with GLP-1 agonist Today, we would like to introduce a demonstration example of a drug efficacy evaluation test targeting GLP-1 using STAMTM mouse. Liraglutide, the first GLP-1 agonist in Japan, was launched on the market in 2010, and since then Exenatide, Lixisenatide, etc. have appeared. As of January 2024, Table…

2025.02.02

Comparative Study of FGF21 agonist

Direct comparison study with FGF21 agonist Today, we would like to introduce a demonstration example of a drug efficacy evaluation study targeting FGF21 using STAMTM mice. In 2023, positive results were announced for Efruxifermin from Akero in the US and Pegozafermin from 89bio in Israel in Phase 2b, and future developments are expected. As…

2025.02.02

Sample delivery service of disease model mice

Today, we would like to proposal on how to utilize samples of our disease model mice. We have provided many drug efficacy evaluation studies, including our STAMTM model is the world’s first NASH to HCC mouse model developed by SMC Laboratories, which develops liver cancer from NASH (non-alcoholic steatohepatitis). We have received many requests…